GHK-Cu Copper Peptide: From a 1973 Plasma Discovery to Copper Chemistry and Matrix Research

GHK-Cu is one of the smallest molecules discussed in peptide research: three amino acids holding a single copper ion. It also has one of the longest research histories, going back more than fifty years. This Vial Post explainer follows that history from a 1973 serum discovery, looks at the coordination chemistry that defines the complex, traces where the GHK sequence comes from in the body's own proteins, and summarizes what fibroblast and wound-chamber experiments actually measured.

Nothing below is guidance on use in people or animals. The Vial Post covers GHK-Cu strictly as a subject of laboratory and literature research.

Quick Facts

• Sequence: glycyl-L-histidyl-L-lysine (GHK), which readily forms a complex with copper(II) known as GHK-Cu (Pickart 2015).
• Where it occurs: human plasma, saliva and urine. A review by the peptide's discoverer puts plasma GHK at about 200 ng/mL at age 20, falling to about 80 ng/mL by age 60 (Pickart 2015).
• First report: a 1973 Nature New Biology paper by Pickart and Thaler on a tripeptide in human serum that prolonged the survival of normal liver cells (Pickart & Thaler 1973).
• Regulatory note: the FDA lists GHK-Cu for injectable routes among bulk substances whose compounding nominations were withdrawn, citing a possible immunogenicity risk, and has scheduled it for advisory committee discussion before the end of February 2027 (FDA bulk substances page; FDA PCAC meeting notice).

Discovery: From an Albumin Fraction to a Tripeptide

According to Pickart's later account, the activity was first noticed in human albumin, where it caused liver tissue from older donors to synthesize proteins in the way younger tissue does. Follow-up work identified the active factor as the tripeptide glycyl-L-histidyl-L-lysine, which binds copper strongly and readily forms the GHK-Cu complex (Pickart 2015). The original 1973 report is the starting point for nearly every later citation (Pickart & Thaler 1973).

How Three Amino Acids Hold a Copper Ion

The geometry of the complex has been pinned down by crystallography and spectroscopy. Hureau and colleagues solved X-ray structures of copper bound to GHK and to DAHK, another naturally occurring copper-binding sequence in blood plasma, and compared them with solution data from EPR, X-ray absorption and NMR (Hureau 2011). Their main findings:

• In solution, Cu(II)-GHK is a monomer with three nitrogen donors to copper: the free amino terminus, a deprotonated amide nitrogen, and the imidazole nitrogen of histidine (Hureau 2011).
• In the crystal, it forms a dimer, and the fourth equatorial position around copper is taken by a labile oxygen atom from a carboxylate group (Hureau 2011).
• Copper moves on and off GHK quickly. Exchange between DAHK peptides is very slow, while exchange involving GHK is fast, which the authors attribute to a complex carrying two GHK molecules per copper (Hureau 2011).
• Redox behaviour: both complexes were inert at moderate redox potentials, but Cu(II)-GHK could be reduced to Cu(I) at around -0.62 V versus Ag/AgCl, releasing the copper ion (Hureau 2011).

Binding strength helps explain why the peptide picks up copper in plasma at all. A review citing earlier measurements gives a log binding constant of 16.44 for GHK versus 16.2 for the high-affinity copper transport site on albumin, so GHK can take copper from albumin (Pickart 2015).

For laboratory work, these results are a reminder that GHK and GHK-Cu are distinct materials and that the copper complex is a dynamic one. The same study examined ternary complexes in which glycine or histidine joins the copper, as well as a species with two GHK molecules per copper (Hureau 2011), so the peptide-to-copper ratio and other ligands in a solution can change which species is present.

Where the GHK Sequence Comes From

Two papers proposed that GHK can be released from larger structural proteins.

• Collagen. Maquart and colleagues pointed out that a GHK triplet occurs in the alpha 2(I) chain of type I collagen, and suggested that proteases might liberate the tripeptide at a wound site (Maquart 1988).
• SPARC. Lane and colleagues showed that proteolysis of SPARC, a matrix-associated protein made by endothelial cells, yields KGHK, GHK and longer peptides containing those sequences. Within the SPARC 113-130 region, the KGHK sequence accounted for most of the angiogenic activity in their assays, and replacing the histidine reduced the effect (Lane 1994).

The SPARC study adds a nuance that often gets lost. Although KGHK bound copper with high affinity, pre-loading it with copper was not needed for activity, and another copper-binding SPARC peptide had no angiogenic effect. The authors concluded the activity was sequence-specific and independent of bound copper (Lane 1994). Copper is central to many GHK-Cu studies, but not every reported activity of GHK-containing peptides depends on it.

What the Matrix Experiments Measured

Collagen synthesis in culture (Maquart 1988). In fibroblast cultures, the copper complex stimulated collagen synthesis starting between 10^-12 and 10^-11 M, with a maximum at 10^-9 M. The increase did not depend on any change in cell number (Maquart 1988).

Proteoglycans in a wound-chamber model (Siméon 2000). In rat experimental wound chambers, GHK-Cu increased wound tissue production, type I collagen and glycosaminoglycans, and enhanced accumulation of chondroitin sulfate and dermatan sulfate. It raised mRNA for the small proteoglycan decorin and lowered that for biglycan in the chambers. In rat dermal fibroblasts, decorin expression rose while biglycan was unchanged (Siméon 2000).

Synthesis and breakdown together. Review literature describes GHK as stimulating both the synthesis and the breakdown of collagen and glycosaminoglycans, and as modulating both metalloproteinases and their inhibitors (Pickart 2015). That two-directional effect is one reason matrix studies need to measure degradation markers as well as synthesis.

Gene-Expression Studies

A 2012 Genome Medicine paper is the most cited example of GHK's use in computational biology. Researchers profiled gene expression in lung tissue regions with differing degrees of emphysematous destruction, then used the Connectivity Map, a gene-profiling tool developed by the Broad Institute (Pickart 2015), to search for compounds with an opposing expression signature. GHK was identified as one. In cultured human fibroblasts, GHK reproduced TGF-beta-like expression patterns, organized the actin cytoskeleton and increased integrin beta 1 expression. Fibroblasts derived from COPD lungs, compared with fibroblasts from former smokers without COPD, showed restored collagen I contraction and remodeling when GHK or TGF-beta was added (Campbell 2012). These are cell-culture and tissue-profiling findings, and the authors themselves called for further mechanistic studies.

Readers should know that the broadest summaries of GHK's activity, such as statements that it up- and down-regulates thousands of human genes, come from reviews co-written by the peptide's discoverer (Pickart 2015), and a later review by the same author group surveys GHK's reported actions in light of gene data (Pickart & Margolina 2018). They are useful maps of the literature, but they are not independent confirmation.

Regulatory Snapshot

On its page of bulk drug substances that may present significant safety risks, the FDA includes GHK-Cu for injectable routes in the list of substances previously in category 2 whose nominations were withdrawn. The agency's note says compounded injectable products containing GHK-Cu may pose a risk of immunogenicity because of possible aggregation and peptide-related impurities, and that human data to inform safety are limited (FDA bulk substances page, accessed October 2026). Separately, the FDA has announced that its Pharmacy Compounding Advisory Committee will meet before the end of February 2027 to discuss GHK-Cu, along with four other substances, for possible inclusion on the 503A bulks list; no date had been posted when this article was updated (FDA PCAC meeting notice, accessed October 2026). For the wider policy background, see our news report on the interim compounding policy.

Questions Readers Ask

What separates GHK from GHK-Cu? GHK is the free tripeptide; GHK-Cu is that tripeptide complexed with copper(II). In solution, the copper is held by three nitrogen atoms from the peptide (Hureau 2011).

Does every GHK effect require copper? No. The angiogenic activity of the related SPARC peptide KGHK did not depend on bound copper (Lane 1994), while the collagen-synthesis work was done with the copper complex (Maquart 1988).

Why does the peptide pick up copper from albumin? Its copper binding constant is reported to be slightly higher than that of albumin's high-affinity copper site (Pickart 2015).

Handling in the Lab

GHK-Cu is usually provided as a lyophilized powder. Typical peptide practice applies: store it cold (commonly -20 degrees C), dry and away from light, prepare solutions only when needed, and avoid repeated freeze-thaw cycles. Confirm identity, copper content and purity against the batch Certificate of Analysis.

For research and educational use only. This article is not medical advice and does not describe dosing or human use.